Efficacy and safety of neoadjuvant pyrotinib plus docetaxel/liposomal doxorubicin/cyclophosphamide for HER2-positive breast cancer

被引：0
|
作者：
Chunyu Tian
Minghui Wang
Hancheng Liu
Jianping Liu
Mengze Xu
Lihui Ma
机构：
[1] Affiliated Hospital of Chengde Medical University,Department of Breast Surgery
[2] Chengde Medical University,School of Nursing
来源：
Irish Journal of Medical Science (1971 -) | 2023年 / 192卷 / 3期
关键词：
HER2; breast cancer; Neoadjuvant therapy; Pathological response; Pyrotinib; TAC;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1041 / 1049
页数：8
相关论文
共 50 条
  • [41] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Giampaolo Bianchini
    Astrid Kiermaier
    Giulia Valeria Bianchi
    Young-Hyuck Im
    Tadeusz Pienkowski
    Mei-Ching Liu
    Ling-Ming Tseng
    Mitch Dowsett
    Lila Zabaglo
    Sarah Kirk
    Tania Szado
    Jennifer Eng-Wong
    Lukas C. Amler
    Pinuccia Valagussa
    Luca Gianni
    Breast Cancer Research, 19
  • [42] Biomarker analysis of the NeoSphere study: pertuzumab, trastuzumab, and docetaxel versus trastuzumab plus docetaxel, pertuzumab plus trastuzumab, or pertuzumab plus docetaxel for the neoadjuvant treatment of HER2-positive breast cancer
    Bianchini, Giampaolo
    Kiermaier, Astrid
    Bianchi, Giulia Valeria
    Im, Young-Hyuck
    Pienkowski, Tadeusz
    Liu, Mei-Ching
    Tseng, Ling-Ming
    Dowsett, Mitch
    Zabaglo, Lila
    Kirk, Sarah
    Szado, Tania
    Eng-Wong, Jennifer
    Amler, Lukas C.
    Valagussa, Pinuccia
    Gianni, Luca
    BREAST CANCER RESEARCH, 2017, 19
  • [43] Pegylated liposomal doxorubicin in combination with cyclophosphamide and trastuzumab in HER2-positive metastatic breast cancer patients: efficacy and cardiac safety from the GEICAM/2004-05 study
    Martin, M.
    Sanchez-Rovira, P.
    Munoz, M.
    Baena-Canada, J. M.
    Mel, J. R.
    Margeli, M.
    Ramos, M.
    Martinez, E.
    Garcia-Saenz, J. A.
    Casado, A.
    Jaen, A. M.
    Gonzalez-Farre, X.
    Escudero, M. J.
    Rodriguez-Martin, C.
    Carrasco, E.
    ANNALS OF ONCOLOGY, 2011, 22 (12) : 2591 - 2596
  • [44] Mechanism, safety and efficacy of three tyrosine kinase inhibitors lapatinib, neratinib and pyrotinib in HER2-positive breast cancer
    Xuhong, Jun-Cheng
    Qi, Xiao-Wei
    Zhang, Yi
    Jiang, Jun
    AMERICAN JOURNAL OF CANCER RESEARCH, 2019, 9 (10): : 2103 - 2119
  • [45] Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
    Andrea Rocca
    Lorenzo Cecconetto
    Alessandro Passardi
    Elisabetta Melegari
    Daniele Andreis
    Manuela Monti
    Roberta Maltoni
    Samanta Sarti
    Elisabetta Pietri
    Alessio Schirone
    Francesco Fabbri
    Caterina Donati
    Oriana Nanni
    Anna Fedeli
    Marina Faedi
    Dino Amadori
    Cancer Chemotherapy and Pharmacology, 2017, 79 : 863 - 871
  • [46] Phase Ib dose-finding trial of lapatinib plus pegylated liposomal doxorubicin in advanced HER2-positive breast cancer
    Rocca, Andrea
    Cecconetto, Lorenzo
    Passardi, Alessandro
    Melegari, Elisabetta
    Andreis, Daniele
    Monti, Manuela
    Maltoni, Roberta
    Sarti, Samanta
    Pietri, Elisabetta
    Schirone, Alessio
    Fabbri, Francesco
    Donati, Caterina
    Nanni, Oriana
    Fedeli, Anna
    Faedi, Marina
    Amadori, Dino
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2017, 79 (05) : 863 - 871
  • [47] Neoadjuvant pyrotinib plus trastuzumab and nab-paclitaxel for HER2-positive early or locally advanced breast cancer: an exploratory phase II trial
    Zhong, Xiaorong
    He, Ping
    Chen, Jie
    Yan, Xi
    Wei, Bin
    Zhang, Zhang
    Bu, Hong
    Li, Jing
    Tian, Tinglun
    Lv, Qing
    Wang, Xiaodong
    Li, Hongjiang
    Wang, Jing
    Huang, Juan
    Suo, Jiaojiao
    Liu, Xiaoxiao
    Zheng, Hong
    Luo, Ting
    GLAND SURGERY, 2022, 11 (01) : 216 - +
  • [48] Current challenges in HER2-positive breast cancer
    Puglisi, Fabio
    Fontanella, Caterina
    Amoroso, Vito
    Bianchi, Giulia Valeria
    Bisagni, Giancarlo
    Falci, Cristina
    Fontana, Andrea
    Generali, Daniele
    Gianni, Lorenzo
    Grassadonia, Antonio
    Moscetti, Luca
    Portarena, Ilaria
    Rossi, Emanuela
    Marchetti, Paolo
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2016, 98 : 211 - 221
  • [49] Pyrotinib Plus Vinorelbine Versus Lapatinib Plus Capecitabine in Patients With Previously Treated HER2-Positive Metastatic Breast Cancer: A Multicenter, Retrospective Study
    Xie, Yizhao
    Li, Yi
    Ting, Luo
    Sang, Die
    Yuan, Peng
    Li, Wei
    Li, Huihui
    Ge, Rui
    Wang, Biyun
    FRONTIERS IN ONCOLOGY, 2021, 11
  • [50] Efficacy of first-line dual oral pyrotinib plus capetabine therapy in HER2-positive metastatic breast cancer: A real-world retrospective study
    Dai, Shuang
    Zhang, Yong
    Tan, Xiang
    Luo, Feng
    Yan, Xi
    CANCER MEDICINE, 2024, 13 (11):
12345